

# Mengtao Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9217403/publications.pdf>

Version: 2024-02-01

177  
papers

3,102  
citations

236925

25  
h-index

254184

43  
g-index

188  
all docs

188  
docs citations

188  
times ranked

3622  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	1.9	185
2	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160
3	Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. <i>Clinical Rheumatology</i> , 2014, 33, 57-63.	2.2	98
4	Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. <i>Molecular Medicine</i> , 2019, 25, 35.	4.4	85
5	JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 334-351.	6.5	83
6	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
7	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , 2017, 236, 432-437.	1.7	81
8	Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). <i>Annals of Translational Medicine</i> , 2020, 8, 1213-1213.	1.7	73
9	Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 251.	3.5	68
10	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. <i>Medicine (United States)</i> , 2016, 95, e2761.	1.0	59
11	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
12	Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study. <i>Rheumatology</i> , 2011, 50, 1640-1644.	1.9	50
13	Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2019, 38, 727-738.	2.2	50
14	High TLR7 Expression Drives the Expansion of CD19+CD24hiCD38hi Transitional B Cells and Autoantibody Production in SLE Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1243.	4.8	49
15	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1800081.	6.7	49
16	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 250-257.	5.8	45
17	High levels of circulating cell-free DNA are a biomarker of active SLE. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13015.	3.4	45
18	Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1441-1443.	0.9	43

#	ARTICLE	IF	CITATIONS
19	The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years. <i>Arthritis Research and Therapy</i> , 2017, 19, 107.	3.5	41
20	Chinese SLE Treatment and Research Group Registry: III. Association of Autoantibodies with Clinical Manifestations in Chinese Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	40
21	Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 791348.	4.8	39
22	Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102691.	5.8	38
23	Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015, 67, 2394-2402.	5.6	34
24	Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. <i>Arthritis Research and Therapy</i> , 2018, 20, 235.	3.5	32
25	Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2017, 44, 1867-1874.	2.0	30
26	Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, e227-e228.	1.9	28
27	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
28	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. <i>European Respiratory Journal</i> , 2020, 56, 1902157.	6.7	27
29	Applications of Next-generation Sequencing in Systemic Autoimmune Diseases. <i>Genomics, Proteomics and Bioinformatics</i> , 2015, 13, 242-249.	6.9	26
30	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 921-928.	1.9	26
31	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.8	26
32	Tofacitinib in patients with refractory Takayasu's arteritis. <i>Rheumatology</i> , 2020, 59, e95-e98.	1.9	26
33	The PD-1/PD-L pathway in rheumatic diseases. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 48-59.	1.7	26
34	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2021, 3, e517-e531.	3.9	26
35	Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. <i>Arthritis Care and Research</i> , 2022, 74, 187-198.	3.4	25
36	Lupus gut microbiota transplants cause autoimmunity and inflammation. <i>Clinical Immunology</i> , 2021, 233, 108892.	3.2	25

#	ARTICLE	IF	CITATIONS
37	Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103084.	5.8	25
38	The renal artery is involved in Chinese Takayasu's arteritis patients. <i>Kidney International</i> , 2018, 93, 245-251.	5.2	24
39	2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020, 1, 5-23.	0.8	24
40	Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. <i>Clinical Rheumatology</i> , 2016, 35, 2501-2507.	2.2	23
41	Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095333.	2.7	23
42	Clinical Features, Morbidity, and Risk Factors of Intestinal Pseudo-obstruction in Systemic Lupus Erythematosus: A Retrospective Case-control Study. <i>Journal of Rheumatology</i> , 2016, 43, 559-564.	2.0	22
43	Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. <i>Lupus</i> , 2020, 29, 795-803.	1.6	22
44	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 111-118.	1.2	22
45	The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. <i>Cancer Communications</i> , 2022, 42, 435-446.	9.2	22
46	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0134451.	2.5	21
47	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1068-1075.	1.9	21
48	Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2019, 38, 2181-2187.	2.2	21
49	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 717-722.	1.9	21
50	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. <i>BioDrugs</i> , 2020, 34, 381-393.	4.6	21
51	CRDC: a Chinese rheumatology research platform. <i>Clinical Rheumatology</i> , 2015, 34, 1347-1352.	2.2	20
52	The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. <i>Scientific Reports</i> , 2016, 6, 38687.	3.3	20
53	Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products. <i>MAbs</i> , 2018, 10, 166-176.	5.2	20
54	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20

#	ARTICLE	IF	CITATIONS
55	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	1.9	20
56	Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 836-840.	0.8	20
57	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
58	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 979-985.	2.2	19
59	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1847-1855.	5.6	18
60	Multimodal photoacoustic/ultrasonic imaging system: a promising imaging method for the evaluation of disease activity in rheumatoid arthritis. <i>European Radiology</i> , 2021, 31, 3542-3552.	4.5	17
61	Association between acute phase reactants, interleukin-6, tumor necrosis factor- $\alpha$ , and disease activity in Takayasu's arteritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 285.	3.5	16
62	Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. <i>BMC Pulmonary Medicine</i> , 2021, 21, 88.	2.0	16
63	Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 669137.	4.8	16
64	Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. <i>Rheumatology</i> , 2021, 60, 2629-2634.	1.9	15
65	The LPS induced pyroptosis exacerbates Bmpr2 signaling deficiency to potentiate SLE $\rightarrow$ PAH. <i>FASEB Journal</i> , 2021, 35, e22044.	0.5	15
66	Correlation of Th17 cells and CD4 $\rightarrow$ CD25 $\rightarrow$ regulatory T cells with clinical parameters in patients with systemic sclerosis. <i>Chinese Medical Journal</i> , 2014, 127, 3557-61.	2.3	15
67	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 21.	3.5	14
68	Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 654-660.	1.9	13
69	Chinese SLE Treatment and Research Group (CSTAR) registry:VIII. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with SLE. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 716-724.	1.9	13
70	Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 609562.	2.6	13
71	Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: a multicenter cross-sectional study. <i>Clinical Rheumatology</i> , 2020, 39, 2677-2688.	2.2	13
72	Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. <i>Arthritis Research and Therapy</i> , 2021, 23, 127.	3.5	13

#	ARTICLE	IF	CITATIONS
73	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 171-175.	0.8	13
74	Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. <i>Journal of Digestive Diseases</i> , 2019, 20, 256-261.	1.5	12
75	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	2.5	12
76	Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e036748.	1.9	11
77	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. <i>Annals of Nuclear Medicine</i> , 2020, 34, 407-414.	2.2	11
78	Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 622216.	4.8	11
79	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	1.9	11
80	Three new inflammatory markers C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio correlated with relapsing polychondritis disease activity index. <i>Clinical Rheumatology</i> , 2021, 40, 4685-4691.	2.2	11
81	Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. <i>Rheumatology</i> , 2022, 62, 256-263.	1.9	11
82	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE. <i>Scientific Reports</i> , 2017, 7, 7617.	3.3	10
83	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2019, 38, 477-485.	2.2	10
84	Inflammation in SLE-PAH: good news or not?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e135-e135.	0.9	10
85	Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	10
86	Activation of Toll-Like Receptor 7 Signaling Pathway in Primary Sjogren's Syndrome-Associated Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 637659.	4.8	10
87	Chinese SLE Treatment and Research group (CSTAR) registry 2009-2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2021, 2, 43-47.	0.8	10
88	Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry. <i>Clinical Rheumatology</i> , 2021, 40, 4597-4608.	2.2	10
89	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10
90	Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies. <i>Frontiers in Immunology</i> , 2021, 12, 783616.	4.8	10

#	ARTICLE	IF	CITATIONS
91	Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. <i>Clinical Rheumatology</i> , 2017, 36, 2727-2732.	2.2	9
92	CD146: a potential therapeutic target for systemic sclerosis. <i>Protein and Cell</i> , 2018, 9, 1050-1054.	11.0	9
93	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1655-1663.	0.4	9
94	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. <i>Frontiers in Immunology</i> , 2020, 11, 568503.	4.8	9
95	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.8	9
96	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 648881.	4.8	9
97	Pilot study of baricitinib for active Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1050-1052.	0.9	9
98	The Role of Anti-U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1788-1789.	5.6	8
99	The Chinese herb <i>Tripterygium wilfordii</i> Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. <i>Clinical Rheumatology</i> , 2020, 39, 813-821.	2.2	8
100	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , 2020, 76, 1161-1168.	2.7	8
101	&lt;p&gt;Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1037-1047.	1.8	8
102	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 152.	2.7	8
103	The current status and challenges in the diagnosis and treatment of rheumatoid arthritis in China: An annual report of 2019. <i>Rheumatology and Immunology Research</i> , 2021, 2, 49-56.	0.8	8
104	Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. <i>Lupus</i> , 2021, 30, 1459-1468.	1.6	8
105	Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. <i>Lupus Science and Medicine</i> , 2022, 9, e000617.	2.7	8
106	Prevalence, predictors and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review. <i>Arthritis Care and Research</i> , 2020, , .	3.4	7
107	Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. <i>Lupus</i> , 2020, 29, 1961-1967.	1.6	7
108	Musculoskeletal ultrasound imaging training, use, and knowledge among rheumatologists in China. <i>Clinical Rheumatology</i> , 2021, 40, 321-330.	2.2	7



#	ARTICLE	IF	CITATIONS
109	The 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Could Classify Systemic Sclerosis Patients at Earlier Stage: Data from a Chinese EUSTAR Center. <i>PLoS ONE</i> , 2016, 11, e0166629.	2.5	7
110	Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry. <i>Rheumatology and Immunology Research</i> , 2021, 2, 195-202.	0.8	7
111	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 291-5.	0.8	7
112	Aberrant glycosylation in autoimmune disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 767-775.	0.8	7
113	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
114	Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 982-990.	1.9	7
115	Lupus nephritis associated with placental site trophoblastic tumor: A case report and review of the literature. <i>Gynecologic Oncology Case Reports</i> , 2014, 9, 26-28.	0.9	6
116	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016, 36, 889-902.	2.2	6
117	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018, 37, 2989-2998.	2.2	5
118	Identification of 6 dermatomyositis subgroups using principal component analysis-based cluster analysis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1383-1392.	1.9	5
119	Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 614482.	2.6	5
120	Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	2.2	5
121	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2021, 40, 1819-1826.	2.2	5
122	Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232098705.	2.5	5
123	Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. <i>Medicine (United States)</i> , 2020, 99, e23184.	1.0	5
124	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 623-632.	0.8	5
125	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 544-550.	0.8	5
126	Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842199808.	2.1	4



#	ARTICLE	IF	CITATIONS
127	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. <i>Clinical Rheumatology</i> , 2021, 40, 4589-4596.	2.2	4
128	220â€¦Clinical characteristics and remission of patients with systemic lupus erythematosus in china: results from SLE treatment and research group (CSTAR) registry with a real-time collecting system. , 2019, , .		3
129	Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during followâ€¦ups and predictors of achieving treatment target. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1719-1727.	1.9	3
130	Clinical features and longâ€¦term outcomes of Chinese patients with scleroderma renal crisis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1194-1200.	1.9	3
131	Aberrant expression of cellâ€¦free nucleosomes in dermatomyositis/polymyositis. <i>Dermatologic Therapy</i> , 2020, 33, e14460.	1.7	3
132	Development and formulation of the classification criteria for osteoarthritis. <i>Annals of Translational Medicine</i> , 2020, 8, 1068-1068.	1.7	3
133	O28â€¦Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a single-center cohort study. , 2020, , .		3
134	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	4.8	3
135	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2021, 8, 618486.	2.6	3
136	Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2021, , .	1.9	3
137	Clinical Characteristics and Prognoses of Patients With Systemic Lupus Erythematosus Hospitalized for Pulmonary Infections. <i>Frontiers in Medicine</i> , 2021, 8, 732681.	2.6	3
138	SMO3, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 1841-1848.	1.9	3
139	The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV). <i>Clinical Rheumatology</i> , 2022, 41, 1371-1379.	2.2	3
140	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	1.7	3
141	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study. <i>Lupus</i> , 2022, 31, 885-890.	1.6	3
142	Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points. <i>Frontiers in Pharmacology</i> , 2020, 11, 606497.	3.5	2
143	A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	2.5	2
144	Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study. <i>Clinical Rheumatology</i> , 2022, 41, 731-739.	2.2	2

#	ARTICLE	IF	CITATIONS
145	Characteristics and long-term outcomes of patients with lupus-related protein-losing enteropathy: A retrospective study. <i>Rheumatology and Immunology Research</i> , 2020, 1, 47-52.	0.8	2
146	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 940-948.	0.8	2
147	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. <i>Lupus Science and Medicine</i> , 2022, 9, e000636.	2.7	2
148	The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020. <i>Rheumatology and Immunology Research</i> , 2022, 3, 38-44.	0.8	2
149	Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	2.5	2
150	Response to letter "Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: Methodological issues". <i>International Journal of Cardiology</i> , 2017, 249, 418.	1.7	1
151	Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 339.	1.7	1
152	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021, 75, e13819.	1.7	1
153	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021, 8, 630660.	2.6	1
154	Immunoglobulin G4-Related Disease Accompanied by Primary Myelofibrosis: Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 638794.	2.6	1
155	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	1.7	1
156	Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 20.	3.5	1
157	Thrombocytopenia Is an Independent Risk Factor for the Prognosis of Thrombotic Microangiopathy in Chinese Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 772607.	2.6	1
158	Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 21, 102996.	5.8	1
159	Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 178-186.	1.6	1
160	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S26-S33.	0.8	1
161	Chinese lupus treatment and research group (CSTAR) registry: X. family history in relation to lupus clinical and immunological manifestations. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 81-87.	0.8	1
162	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1

#	ARTICLE	IF	CITATIONS
163	Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1052-1054.	0.9	1
164	Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy. <i>Rheumatology and Immunology Research</i> , 2022, 3, 23-30.	0.8	1
165	Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	1
166	Structural and Functional Characterization of Gray Matter Alterations in Female Patients With Neuropsychiatric Systemic Lupus. <i>Frontiers in Neuroscience</i> , 2022, 16, 839194.	2.8	1
167	Clinical characteristics and outcomes of lupus myocarditis: a retrospective case control study in Chinese patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
168	AB0387â€¦SATISFACTION OF PATIENTS AND PHYSICIANS WITH TREATMENTS FOR RHEUMATOID ARTHRITIS: A NATIONWIDE SURVEY IN CHINA. , 2019, , .		0
169	247â€¦New organ involvement development during follow-up of patients with systemic lupus erythematosus in China: a Multi-center cohort study from CSTAR registry. , 2019, , .		0
170	33â€¦Composite goals plus inflammation: further risk assessment for systemic lupus erythematosus associated pulmonary arterial hypertension in CSTAR-PAH cohort. , 2019, , .		0
171	Risk factors for progression of carotid intima-media thickness in patients with systemic lupus erythematosus: protocol for an observational cohort study in China. <i>BMJ Open</i> , 2019, 9, e030721.	1.9	0
172	P157â€¦Update on the real-time collecting system data of SLE treatment and research group (CSTAR) registry: clinical features and remission of patients with systemic lupus erythematosus in China. , 2020, , .		0
173	O27â€¦Development and validation of a multivariable model for 5-year survival in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. , 2020, , .		0
174	P10â€¦Antiphospholipid antibodies associated extra-criteria clinical manifestations should not be ignored. , 2020, , .		0
175	P11â€¦Early efficient anticoagulation improves the long-term prognosis in patients with antiphospholipid syndrome associated portal vein thrombosis. , 2020, , .		0
176	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. <i>Rheumatology and Immunology Research</i> , 2021, 2, 63-78.	0.8	0
177	A 16-year-old boy with arthritis, rash, and hemoptysis: Beyond â€œundifferentiated connective tissue diseaseâ€œ?. <i>Rheumatology and Immunology Research</i> , 2022, 3, 46-50.	0.8	0